Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The natural histories of, and treatment options for, epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers (NSCLCs) are distinctly different from those of lung cancer that lacks actionable mutations. Ipilimumab is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor that has been approved in other malignancies.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Target Oncol

Title: Targeted oncology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1776-260X

ISSN (Print): 1776-2596

Publication date (Electronic): August 2019

Volume: 14

Issue: 4

Affiliations

[1 ] Huntsman Cancer Institute, University of Utah, 1950 Cir of Hope Dr, Salt Lake City, UT, 84112, USA. Anna.chalmers@hci.utah.edu.

[2 ] Huntsman Cancer Institute, University of Utah, 1950 Cir of Hope Dr, Salt Lake City, UT, 84112, USA.

[3 ] Utah Cancer Specialists, Salt Lake City, UT, USA.

[4 ] Dana-Farber Cancer Institute, Boston, MA, USA.

Article

Publisher Item ID: 10.1007/s11523-019-00658-0

DOI: 10.1007/s11523-019-00658-0

PubMed ID: 31346927

SO-VID: 2d7c9eec-0f97-4ec4-873d-e386eb96082c

History

Data availability:

Comments

Comment on this article

scite_

Cited by 21

See all cited by